
Bio Break: Understanding Continuous Glucose Monitors
Continuous glucose monitors (CGMs) are revolutionizing how people track blood sugar levels in real time. But how do they work, and where exactly do they measure glucose? In this episode of Bio Break, Nick and Joris explore the science behind CGMs, explaining the difference between blood glucose monitoring and interstitial fluid measurement—and why CGMs don’t actually draw blood continuously.
Rather than inserting a sensor directly into a vein, CGMs use microneedles or tiny tubes that sit in the interstitial fluid, the liquid surrounding the body’s cells. Unlike blood, which flows within veins, interstitial fluid is more accessible for continuous monitoring. However, there’s a key tradeoff—glucose levels in interstitial fluid lag behind blood glucose levels by about 5-10 minutes. This means CGMs don’t provide an instant blood sugar reading but rather a near-real-time estimate.
Nick raises an important question: does this time lag matter for diabetes management or sports performance tracking? Joris explains that while this delay exists, CGMs still offer huge advantages over traditional blood testing, which often requires finger pricks or lab draws that provide only a single data point. The ability to continuously measure glucose, lactate, or other small molecules gives users a clearer picture of how their body responds to food, exercise, and lifestyle changes.
However, not everything can be measured using interstitial fluid. Large molecules like hormones, red blood cells, and protein-bound compounds don’t diffuse as easily into interstitial fluid, making them difficult to track with a CGM. But for small molecules such as glucose, lactate, histamine, and creatinine, interstitial fluid monitoring is a powerful tool for real-time insights into metabolism.
If you’ve ever wondered how CGMs work or why they don’t require direct blood sampling, this episode breaks down the technology in a simple, engaging way.
Understanding Continuous Glucose Monitors
Related Resources

Nick Allan and Nigel Syrotuck share their end-of-summer reading list, featuring FDA regulatory books and PCR memoirs. From navigating regulatory hurdles to celebrating groundbreaking discoveries, their choices show how science reading can be both educational and entertaining.

While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.

Nigel Syrotuck and Nick Allan explore the surprising reality of inhaler spacer use. While these devices are often thought of as tools for children with asthma, research shows that adults struggle with them too.

Radiopharmaceutical device development is gaining momentum as medical teams explore new frontiers in diagnostic imaging and cancer treatment.